Armstrong Advisory Group’s Teva Pharmaceuticals TEVA Stock Holding History

Armstrong Advisory Group’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.15K	Hold	93	–	–	﹤0.01%	842
2026 Q1	$2.8K	Hold	93	–	–	﹤0.01%	840
2025 Q4	$2.9K	Hold	93	–	–	﹤0.01%	826
2025 Q3	$1.88K	Buy	+93	New	+$1.63K	﹤0.01%	866

Other funds holding TEVA

Assenagon Asset Management

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Silverberg Bernstein Capital Management Armonk, New York $261M AUM 89.93% 1-Year Est. Return

Armstrong Advisory Group's TEVA Position: Q2 2026 in Review

Armstrong Advisory Group held its Teva Pharmaceuticals (TEVA) position steady in Q2 2026 at 93 shares worth $3.15K. The position accounts for ﹤0.01% of the portfolio, ranked #842.

Armstrong Advisory Group first reported a position in TEVA in Q3 2025 and has held it in 4 quarters since. 90 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Armstrong Advisory Group held 93 shares of Teva Pharmaceuticals worth $3.15K as of Q2 2026.
Armstrong Advisory Group left its Teva Pharmaceuticals share count unchanged in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Armstrong Advisory Group's portfolio in Q2 2026, its #842 holding.
Armstrong Advisory Group first reported a position in Teva Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
90 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Armstrong Advisory Group's 13F filing for Q2 2026, filed 13 Jul 2026.